London-based AI startup Boltz has secured $110 million in a Series A funding round. The company, which focuses on accelerating drug discovery through AI models, emerged from stealth less than a year ago. The startup was originally spun out of MIT and currently maintains its headquarters in London, where it employs 40 AI researchers in the King's Cross district.

Bessemer Venture Partners led the latest investment round. Existing investors, including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures, also participated. New backers include Greycroft, F-Prime Capital, Hummingbird, and Benchling. Nvidia also joined the list of investors following an announcement earlier this year. Previously, the company raised a $28 million seed round.

The startup develops software that assists researchers in designing potential drugs and selecting candidates for laboratory testing. Its AI models predict protein-drug binding, estimate binding strength, and propose new molecules. Boltz provides access to its technology through a platform and API, offering both open-source and proprietary models. The company has established collaborations with Pfizer, GSK, Takeda, and Bristol Myers Squibb.